超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國 豪洛捷 Hologic
Hologic公司于1986年由前任總裁和董事長S. David Ellenboger和首席技術總監Jay A. Stein創辦，是一家致力于滿足女性健康醫療，提供最先進的醫學影像系統的公司。

　　Hologic公司自創辦起，就一直致力于開發和提供日益發展的醫學影像系統，以滿足現代醫學女性健康醫療的需要。它首先開發出最先進的放射學數字影像技術并應用于乳腺照像。當前Hologic公司的業務主要集中在骨質疏松檢測系統、乳腺照像和乳腺活組織檢測系統、數字化X線檢測系統以及適用于骨科小型C型臂檢測系統。

　　1987年，Hologic公司在骨密度檢測方法中取得突破，是首家推出雙能X線骨密度儀（DXA）的公司。目前Hologic公司還在不斷開發、生產和銷售X線骨密度儀和超聲骨分析儀，以用于臨床骨質疏松的預防和治療。公司生產的是數字化放射檢測系統（QDR）已在X線骨密度儀中得到應用，通過精確測量骨密度，大大提高了骨質疏松癥的診斷水平，并能對包括骨質疏松在內的骨代謝疾病的治療進行良好的監測。

　　Hologic公司正在繼續努力以保證其在該領域的領先水平，最引人注目的是最近新研發生產的Discovery QDR系列骨密度儀和脊椎快速評價技術的應用。

　　Hologic公司生產的骨密度儀目前已遍布許多先進的醫學院校、研究機構和骨質疏松領域里一些著名專家的實驗室。在全球已有10000臺在工作.

Hologic, Inc. (NASDAQ: HOLX) is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women throughout the world.

Historically, Hologic developed, manufactured, and marketed products focused on mammography, breast care, and osteoporosis assessment. In 2007, we expanded our focus and now provide a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arms for extremity imaging, and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. We are proud of this achievement, and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company.

Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health.

Breast Health

"You have cancer. Fortunately, we caught it early."

Hologic's largest business is breast cancer diagnosis and treatment. Each year, more than one million women in the U.S. are diagnosed with breast cancer, while hundreds of thousands of them fall victim to this dreaded disease. One out of eight American women will get breast cancer in her lifetime. Fortunately when breast cancer is detected and treated in its earliest stages, the five-year survival rate is 98 percent.

In 2007, 92 percent of the mammography breast cancer screening systems sold in the United States were digital. The Hologic Selenia? system is at the forefront of this wave, setting a standard for excellence in digital mammography.

We continue to introduce advances in imaging and interpretation, such as the first tungsten x-ray tube with a special silver filter that allows digital mammography images to be acquired at a lower radiation dose and shorter exposure times. We have integrated the R2? computer-aided detection (CAD) into our SecurView? diagnostic workstations, giving clinicians a sophisticated pattern recognition software tool to help find cancers at an early stage.

Hologic is helping imaging centers deliver a "high-tech, soft-touch" experience with the MammoPad? radiolucent breast cushion. The MammoPad cushion provides patient comfort, while aiding in breast positioning, compression, and tissue acquisition.

Each year in the U.S. there are more than 600,000 open surgical breast biopsies. An estimated 80 percent of results are negative. The cost, risk, and trauma of these surgeries are enormous. Less invasive alternatives can drive down healthcare costs, support clinical efficiency, and, most importantly, cause far less distress for patients. Just as we are at the forefront of driving better detection solutions, our goal is to lead the industry in developing innovative technologies that make less invasive and more effective intervention possible and preferred.

Our MultiCare? Platinum stereotactic prone biopsy table and StereoLoc? II and digital StereoLoc II breast biopsy systems are designed to facilitate highly precise, image-guided procedures under minimally invasive conditions. We offer a wide number of interventional breast biopsy solutions including ATEC? percutaneous, automatic vacuum assisted breast biopsy systems, Celero? and Eviva? ancillary biopsy devices, and a full line of biopsy site markers designed to provide compassionate care for every woman facing a breast cancer diagnosis.

When a cancer diagnosis is confirmed and radiation treatment is required, our MammoSite? targeted radiation therapy gives women a less traumatic alternative to mastectomies and whole breast irradiation. Using MammoSite therapy, clinicians can deliver a site-specific radiation dose inside the breast, reducing exposure to surrounding healthy tissue and organs. Four-year analysis of the MammoSite radiation therapy system has found that breast cancer recurrence rates with the MammoSite system continue to be comparable to the rates reported with standard radiation therapy.